Amifostine
Ethyol (amifostine) is a small molecule pharmaceutical. Amifostine was first approved as Ethyol on 1995-12-08. It is used to treat experimental radiation injuries in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ethyol
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ethyol | New Drug Application | 2023-11-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| experimental radiation injuries | — | D011833 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0207 | Injection, amifostine, 500 mg |
Clinical
Clinical Trials
84 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 4 | 13 | 1 | 1 | 1 | 16 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 10 | 1 | 1 | 1 | 14 |
| Neoplasms | D009369 | — | C80 | 6 | 5 | 1 | 1 | 1 | 13 |
| Lymphoma | D008223 | — | C85.9 | 3 | 4 | — | 1 | — | 7 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 8 | 1 | — | — | 10 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | 1 | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | 1 | — | — | 2 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | — | 1 | — | — | 1 |
| Trophoblastic neoplasms | D014328 | — | — | — | — | 1 | — | — | 1 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | — | 1 | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | — | 1 | — | — | 1 |
| Hepatoblastoma | D018197 | — | C22.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 8 | — | — | — | 9 |
| Leukemia | D007938 | — | C95 | 6 | 6 | — | — | — | 9 |
| Sarcoma | D012509 | — | — | 2 | 4 | — | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 4 | — | — | — | 5 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 3 |
| Mucositis | D052016 | EFO_1001898 | — | — | 3 | — | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | 3 | — | — | — | 3 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 2 | 2 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 1 | 2 | — | — | — | 2 |
| Neutropenia | D009503 | — | D70 | — | 2 | — | — | — | 2 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | — | — | 2 | — | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Retinoblastoma | D012175 | — | — | 1 | — | — | — | — | 1 |
| Chordoma | D002817 | EFO_0000334 | — | 1 | — | — | — | — | 1 |
| Acute radiation syndrome | D054508 | — | — | 1 | — | — | — | — | 1 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Precancerous conditions | D011230 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amifostine |
| INN | amifostine |
| Description | Amifostine is an organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy. It has a role as a prodrug, a radiation protective agent and an antioxidant. It is a diamine and an organic thiophosphate. It is functionally related to a cysteamine. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCCNCCSP(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 20537-88-6 |
| RxCUI | 1545987 |
| ChEMBL ID | CHEMBL1006 |
| ChEBI ID | 2636 |
| PubChem CID | 2141 |
| DrugBank | DB01143 |
| UNII ID | ILA426L95O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ethyol – Cumberland Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,375 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
750 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use